Nacionalinis Vezio Institutas

Az itteni vizsgálatok

Miről szól a helyszín 20 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek

• Tüdőrák7 vizsgálat
• Melanóma6 vizsgálat
• Gyomor- és nyelőcsőrák3 vizsgálat
• Fej-nyaki daganatok2 vizsgálat
• Petefészekrák2 vizsgálat
• Prosztatarák2 vizsgálat
• Hólyagrák1 vizsgálat
• Méhtestrák1 vizsgálat
• Vesedaganat1 vizsgálat

Fázis

• 3. fázis13 vizsgálat
• 1. fázis4 vizsgálat
• 2. fázis2 vizsgálat
• 2/3. fázis1 vizsgálat

Állapot

• Lezárult17 vizsgálat
• Fut, nem toboroz3 vizsgálat

Fő szponzor

• H e x a l AG3 vizsgálat
• Merck Sharp & Dohme LLC3 vizsgálat
• Amgen Inc.2 vizsgálat
• Bayer2 vizsgálat
• AGO Research GmbH1 vizsgálat
• és még 9

Futó vizsgálatok

• Fut, nem toboroz

  A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

  NCT06496178· 3. fázis· Genmab· Forrás

• Fut, nem toboroz

  A Study to Evaluate ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Unresectable or Metastatic Melanoma

  2023-503288-40-00· 3. fázis· Amgen Inc.· Forrás

• Fut, nem toboroz

  Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer

  NCT03540420· 2. fázis· Norwegian University of Science and Technology· Forrás

Lezárt vizsgálatok

• Lezárult

  Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® in combination with Yervoy®

  NCT06587451· 3. fázis· H e x a l AG· Forrás

• Lezárult

  A study to compare effects and safety of CT-P51 and Keytruda in patients with previously untreated metastatic lung cancer

  2024-514048-98-00· 3. fázis· Celltrion Inc.· Forrás

• Fut, nem toboroz

  A study to continue providing GME751 (a new medicine that is similar to pembrolizumab) to participants who are eligible for pembrolizumab treatment after participation in previous studies (CGME751A12101 or CGME751A12301)

  2024-513160-25-00· 3. fázis· H e x a l AG· Forrás

• Lezárult

  A Pharmacokinetics (PK) study to compare GME751 (proposed pembrolizumab biosimilar) and United States (US)-licensed and European Union (EU)-approved Keytruda®in participants with stage Ⅱ and Ⅲ skin cancer requiring adjuvant treatment (therapy applied after initial treatment of cancer to suppress the regrowth of tumor) with pembrolizumab.

  2023-506881-30-00· 1. fázis· H e x a l AG· Forrás

• Lezárult

  Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

  2022-502196-31-00· 2/3. fázis· Kartos Therapeutics Inc.· Forrás

• Lezárult

  A Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Stage III and Stage IV Melanoma in the Adjuvant Setting

  2022-502620-49-00· 1. fázis· Amgen Inc.· Forrás

• Lezárult

  Study of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

  NCT05092360· 3. fázis· Mural Oncology Inc.· Forrás

• Lezárult

  A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

  NCT05568095· 3. fázis· Arcus Biosciences, Inc.· Forrás

• Lezárult

  An open-label, phase I multicenter, clinical trial of NECVAX-NEO1 in addition to anti-PD-1 or anti-PD-L1 monoclonal antibody checkpoint inhibitor monotherapy in patients with solid tumors

  2024-513716-95-00· 1. fázis· Nec Oncoimmunity AS· Forrás

• Lezárult

  Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05052801· 3. fázis· Amgen· Forrás

• Lezárult

  Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer

  NCT04736199· 3. fázis· Bayer· Forrás

• Lezárult

  A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones

  NCT04521361· 1. fázis· Bayer· Forrás

• Fut, nem toboroz

  Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

  NCT04380636· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Lezárult

  First line treatment with osimertinib in non-small cell lung cancer, coupled with studies on biological samples.

  NCT03804580· 2. fázis· Vestre Viken HF· Forrás

• Lezárult

  Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

  NCT03353831· 3. fázis· AGO Research GmbH· Forrás

• Fut, nem toboroz

  Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

  NCT03425643· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Lezárult

  Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

  NCT03221426· 3. fázis· Merck Sharp & Dohme LLC· Forrás